Patent 10865400

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (3)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

2016-08-05 · reel 035651/0177 · Assignment of Assignors Interest
CONNOR, ROBERT JAMES, WEI, GE, ZHAO, Qiping HALOZYME THERAPEUTICS, INC.
Correspondent: Matthew S. Blundell, PhD
internal reorg
2016-08-05 · reel 035651/0187 · Assignment of Assignors Interest
HALOZYME THERAPEUTICS, INC.HALOZYME, INC.
Correspondent: Matthew S. Blundell, PhD
internal reorg
2016-08-05 · reel 035651/0204 · Assignment of Assignors Interest
SHEPARD, H. MICHAEL HALOZYME, INC.
Correspondent: Matthew S. Blundell, PhD
internal reorg

Assignment history

✓ Generated

Inventors

Ge Wei
H. Michael Shepard
Qiping Zhao
Robert James Connor

Employer at the time of filing: Halozyme Inc. (original assignee)
Unusual patterns: Not determinable from the provided information if inventors departed the original assignee within 12 months of filing.

Original assignee

Halozyme Inc.
Halozyme Therapeutics Inc. (Current Assignee)
Product embodying the claims: US10865400 describes "PH20 polypeptide variants, formulations and uses thereof," which are related to hyaluronidase enzymes. Halozyme Therapeutics, Inc. develops and commercializes "ENHANZE®" drug delivery technology, which utilizes a recombinant human hyaluronidase enzyme (rHuPH20) to facilitate the subcutaneous administration of co-administered therapeutics. This technology appears to embody the claims of the patent.
Primary line of business: Halozyme Therapeutics, Inc. is a biotechnology company focused on novel oncology and rare disease therapies, and also has a proprietary enzyme technology (ENHANZE®) that facilitates the delivery of injected drugs.
Current status: Operating.

Assignment timeline

2016-08-05 (executed) / recorded 2016-08-05 — Reel 035651/0177
- Conveyance: Assignment of Assignors Interest
- Assignor: CONNOR, ROBERT JAMES; WEI, GE; ZHAO, Qiping
- Assignee: HALOZYME THERAPEUTICS, INC.
- Correspondent: Matthew S. Blundell, PhD, Halozyme, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121
- Context: Internal reorg (transfer from individual inventors to corporate entity)
2016-08-05 (executed) / recorded 2016-08-05 — Reel 035651/0187
- Conveyance: Assignment of Assignors Interest
- Assignor: HALOZYME THERAPEUTICS, INC.
- Assignee: HALOZYME, INC.
- Correspondent: Matthew S. Blundell, PhD, Halozyme, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121. This correspondent recurs in this chain.
- Context: Internal reorg (transfer between related corporate entities)
2016-08-05 (executed) / recorded 2016-08-05 — Reel 035651/0204
- Conveyance: Assignment of Assignors Interest
- Assignor: SHEPARD, H. MICHAEL
- Assignee: HALOZYME, INC.
- Correspondent: Matthew S. Blundell, PhD, Halozyme, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121. This correspondent recurs in this chain.
- Context: Internal reorg (transfer from individual inventor to corporate entity)

Timeline diagram

timeline
    title Ownership of US 10865400
    2016 : Inventors assign to Halozyme Therapeutics
         : Halozyme Therapeutics assigns to Halozyme Inc
         : Inventor H.M. Shepard assigns to Halozyme Inc
    2020 : Patent issued to Halozyme Inc
    2025 : Litigation filed in New Jersey District
    2026 : PTAB case IPR2026-00312 filed

NPE / troll-pattern signals

Shell-entity transfer — not present. All transfers are between Halozyme entities or individual inventors and Halozyme entities.
Known asserter in the chain — not present. Halozyme Inc. and Halozyme Therapeutics, Inc. are operating companies.
Repeat correspondent across the chain — present. Matthew S. Blundell, PhD, of Halozyme, Inc. is listed as the correspondent for all three recorded assignments. This indicates an internal legal counsel handling assignments for the same operating company.
Cascading transfers — not present. While there are three assignments on the same day, they represent internal transfers from inventors to the company and between closely related corporate entities of Halozyme.
Pre-litigation transfer — not present. The recorded assignments occurred in 2016, and the first litigation case found for this patent was filed in 2025.
Bankruptcy fire-sale — not present. Halozyme Inc. is an operating company.
Privateering — not present. The patent remains with the original operating company.
Defensive aggregator (anti-NPE) — not present. The current assignee is an operating company, not a defensive aggregator.

Verdict

Operating-company assertion
The assignment records clearly show the patent has remained within the Halozyme corporate family since its inception, with all transfers being internal reorganizations. Halozyme Therapeutics, Inc. is an operating company that commercializes products directly related to the patent's claims.

USPTO Assignment Center search for US10865400: https://assignment.uspto.gov/patent/index.html?ref=advanced_search&patent_number=10865400

Generated 5/29/2026, 5:54:42 PM